Analysts Offer Insights on Financial Companies: Robinhood (HOOD) and Upstart Holdings (UPST)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Robinhood (HOOD)
In a report released today, Gautam Chhugani from Bernstein maintained a Buy rating on Robinhood, with a price target of $160.00. The company's shares closed last Monday at $115.02.
According to TipRanks.com, Chhugani is a 5-star analyst with an average return of 50.5% and a 66.2% success rate. Chhugani covers the Financial sector, focusing on stocks such as Coinbase Global, Riot Platforms, and Iris Energy. ;'>
Currently, the analyst consensus on Robinhood is a Moderate Buy with an average price target of $111.68, representing a -1.2% downside. In a report issued on August 4, Compass Point also maintained a Buy rating on the stock with a $105.00 price target.
Upstart Holdings (UPST)
Compass Point analyst Giuliano Bologna reiterated a Sell rating on Upstart Holdings today and set a price target of $20.00. The company's shares closed last Monday at $65.30.
According to TipRanks.com, Bologna is a 4-star analyst with an average return of 10.4% and a 58.9% success rate. Bologna covers the Financial sector, focusing on stocks such as Chime Financial, Inc. Class A, MGIC Investment, and Guild Holdings. ;'>
Upstart Holdings has an analyst consensus of Hold, with a price target consensus of $66.64.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
28 minutes ago
- CTV News
Humpy Wheeler, the ‘P.T. Barnum of motorsports,' dies at 86
H.A. "Humpy" Wheeler, president and general manager of Lowe's Motor Speedway, pays up for being late to the news conference to announce the burnout contest that will be held during the pre-race show before the start of the NASCAR Sprint All-Star Race during a new conference at Lowe's Motor Speedway on April 22, in Concord, N.C. (AP Photo/Rick Havner) CHARLOTTE, N.C. — Humpy Wheeler, a pioneering motorsports promoter and former president and general manager of Charlotte Motor Speedway, has died, NASCAR said. He was 86. Charlotte Motor Speedway said Wheeler died of natural causes Wednesday in Charlotte, surrounded by his family. ADVERTISEMENT 'Humpy Wheeler was a visionary whose name became synonymous with promotion and innovation in our sport,' said NASCAR chairman Jim France. 'During his decades leading Charlotte Motor Speedway, Humpy transformed the fan experience through his creativity, bold ideas and tireless passion. His efforts helped expand NASCAR's national footprint, cement Charlotte as a must-visit racing and entertainment complex.' Howard Augustine Wheeler Jr. was born in 1938 in Belmont, North Carolina, and gained his first major publicity job with Firestone Tire and Rubber Company. He held several other positions after Firestone shut down its racing program in 1970 and was hired at Charlotte Motor Speedway by owner Bruton Smith as president in 1975. He became a transformative figure in promoting racing and was known as the 'P.T. Barnum of motorsports' for flashy pre-race stunts, elaborate productions and sparing no expense in ensuring fans had the most enjoyable experience possible at his events. Wheeler earlier this year was named winner of NASCAR's prestigious Landmark Award for Outstanding Contributions to NASCAR, to which he'd have been inducted into the Hall of Fame next year. 'Humpy's contributions to and accomplishments in NASCAR are without parallel. The breadth and depth of his legacy, and those whom he influenced, assisted and mentored, cannot be overstated,' said Winston Kelley, executive director of the Hall of Fame. 'Frequently adding new dynamics to the sport, Humpy's visionary leadership and creativity helped shape today's fan experience. 'Through his innovative promotions and stunts, Wheeler's contributions expanded NASCAR's national and international presence during the 1990s and early 2000s, solidifying Charlotte as 'NASCAR's Home for Racing.'' Wheeler mentored 'hundreds, if not thousands,' of people throughout his life, Kelley said, including inaugural NASCAR Hall of Famer Dale Earnhardt and Landmark Award recipient Janet Guthrie. Wheeler spent 33 years running Charlotte Motor Speedway. His innovation and pre-race extravaganzas recreated numerous military operations — including the invasion of Grenada — that made the facility a gold standard in NASCAR. He promoted school-bus races during the week, grassroots series for young aspiring racers, stunts and even the 'Robosaurus,' a towering, fire-breathing, car-crunching mechanical robot. Wheeler and his boss, the late Smith, grew Charlotte Motor Speedway into the ownership group Speedway Motorsports Inc., which acquired multiple race tracks that play a pivotal role in American motorsports today. Charlotte was the first track to build condominiums on site, built a restaurant overlooking the race track and was the first speedway of its size to install lights for night racing. 'Charlotte Motor Speedway was blessed to have a leader in Humpy Wheeler who can only be described as ONE of a kind,' the speedway said in a statement. ' For more than 30 years, Humpy was a promoter's promoter at Charlotte Motor Speedway. Alongside our founder Bruton Smith, Humpy pushed the speedway to new and greater heights — establishing the famed 1.5-mile superspeedway as not only the most innovative facility in NASCAR for fan, partner and competitor amenities, but also one of the most progressive in all of sports. 'Humpy's engaging smile and flair for promotion were legendary, and his impact on every stakeholder in motorsports will be long-lasting. Humpy not only made his mark with publicity, but also with a laser-focus toward the fans,' the speedway continued. 'He would often tell his staff to pay attention to 'the three Ts — tickets, traffic and toilets,' in order to ensure fans have the best possible experience. He would also say it was our job to put a little 'technicolor in people's black-and-white lives.'" Wheeler retired from Charlotte Motor Speedway and Speedway Motorsports in 2008 after a bitter falling out with Smith, but remained active in motorsports through his own consulting company and was on the voting panel for the NASCAR Hall of Fame. He is survived by his wife, Pat; daughters, Traci and Patti; son, Trip; and four grandchildren. Funeral arrangements are pending and the family request donations be made in Wheeler's name to the Belmont Abbey College Motorsports Management Program, which Wheeler was instrumental in launching more than 20 years ago. ___ Jenna Fryer, The Associated Press
Globe and Mail
28 minutes ago
- Globe and Mail
FDA Extends Review Period of REGN's Submission for Eylea HD
Regeneron Pharmaceuticals, Inc. ( REGN ) announced that the FDA has extended the target action dates for Eylea HD (aflibercept) injection 8 mg regulatory submissions. Eylea HD is the higher dose of Eylea. The regulatory body has now extended the target action dates to the fourth quarter of 2025 for two regulatory submissions for Eylea HD (aflibercept) Injection 8 mg. The submission includes a Chemistry, Manufacturing and Controls Prior-Approval Supplement for the Eylea HD prefilled syringe and a supplemental biologics license application seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications. Despite the extension announcement, REGN shares were up 3.4%. This information was previously communicated by the company during its second-quarter earnings release. This is probably because Eylea HD remains available in the United States through vial administration. Regeneron's shares have lost 17% year to date against the industry 's gain of 3.8%. More on REGN's Eylea HD The FDA extended the review periods after determining that the information submitted following a recent inspection of a third-party manufacturer constituted a major amendment to each application. The anticipated delay resulted from observations during an FDA general site inspection of Catalent Indiana LLC, which Novo Nordisk A/S ( NVO ) acquired in December 2024. Novo Nordisk submitted a comprehensive response in early August 2025 to address the observations noted by the FDA. Eylea HD is approved with dosing intervals every 8 to 16 weeks for patients with wet age-related macular degeneration and diabetic macular edema, and every 8 to 12 weeks for patients with diabetic retinopathy, following three initial monthly doses. Eylea HD (known as Eylea 8 mg in the European Union and Japan) is being jointly developed by Regeneron and Bayer AG ( BAYRY ). While Regeneron holds exclusive rights to Eylea and Eylea HD in the United States, BAYRY holds the exclusive marketing rights outside the country. REGN and BAYRY equally share the profits from sales of Eylea and Eylea HD. REGN Banks on Eylea HD and Dupixent for Growth Regeneron's performance in the second quarter was encouraging. The company has finally managed to post revenue growth despite declining sales of lead drug Eylea. Eylea sales continue to decline due to competition from Vabysmo. To counter the decline in Eylea sales, Regeneron has developed a higher dose of the drug. Eylea HD sales in the United States surged 29% in the second quarter due to higher sales volumes driven by increased demand. REGN's top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi ( SNY ) records global net product sales of Dupixent. SNY and REGN are working to expand the drug's label further. The FDA had earlier approved Dupixent for chronic obstructive pulmonary disease (COPD). The approved indication is an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. Consistent label expansions of Dupixent continue to fuel its sales and help REGN earn higher profits. REGN is looking to strengthen its oncology portfolio to diversify its revenue stream. The recent progress with its oncology pipeline has been encouraging. The approval of Lynozyfic is a boost for its oncology portfolio. Zacks Rank Regeneron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
Globe and Mail
28 minutes ago
- Globe and Mail
Nutriband (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity
FDA grants Type C Meeting for AVERSA(TM) Fentanyl to discuss Chemistry, Manufacturing, and Controls pathway from IND submission through NDA approval and commercialization CEO Gareth Sheridan temporarily steps aside to pursue Irish Presidential nomination while Chairman Serguei Melnik assumes interim CEO role during critical development phase Strategic partnership with Kindeva combines proven FDA-approved fentanyl patch technology with Nutriband's proprietary abuse-deterrent platform targeting $80-200 million peak U.S. market opportunity The pharmaceutical development landscape presents a fundamental shift as regulatory frameworks evolve beyond traditional efficacy-first approaches. The most significant patient impact now comes from innovations that enhance safety profiles of existing therapeutic options, particularly in pain management where the balance between therapeutic benefit and abuse potential creates urgent medical need alongside substantial regulatory complexity. The opioid crisis has reshaped how regulators approach pain management solutions. The most promising opportunities exist at the intersection of proven therapeutic benefit and enhanced safety mechanisms, requiring both technological innovation and regulatory expertise to navigate complex approval… Read More>> About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire San Francisco, CA 415.949.5050 Office Editor@ BioMedWire is powered by IBN
